NGOncology is based on target sequencing with TruSightCancer Panel (Illumina) by massive parallel sequencing (NGS). The test differs from some of our other genetic tests, offeringparallel analysis of 94 genes instead of one or more. The selected genes are suspected to play a key role in predisposing to cancer – associated with both common (breast, ovarian, colorectal) and rare cancers. The results are analyzed by using massive international data bases.

The test is highly informative and can be used to prevent the development or progression of existing oncological diseases as well as to clarify the risks, allowing opportunity for prevention andearly diagnosis among the youngest family members.

NGOncology is followed by thorough genetic consultation and detailed summary aimed at clarifying the customer’s information, discussing the results and redirecting the client to the appropriate specialist if needed.

The aim of NGOncologyis to become part of our portfolio to offer general detailed care to our patients. We believe it is our mission to help prevent serious diseases or improve the quality of life when an illness is already present.

The genetic testing requires DNA isolation from blood.

Venous blood collection should be performed with the use of closed vacuum blood collection system, following standard sterile procedures in convenient clinical laboratory for the client, and transported at room temperature to our partner genetic laboratory. The blood should be collected in EDTA vacuum tubes (Ethylene Diamine Tetraacetic A), which you will find in the test order kit. The sample volume should be no less than 4 ml.

The results will be completed within 4 to 8 weeks from the date of sample submission. You will receive e-mail informing you of the way you can access them. The cost of the test includes consultation with genetics practitioner trained in interpreting the results to help you understand your genetic predisposition to oncological diseases. Our specialists will outline specific steps to prevent illness development or facilitate the treatment process.

The risk that exists in the presence of mutations in genes associated with cancer remains throughout the individual’s life. Therefore, the information that you receive is not temporary and applies permanently until the rest of your life. However, in most cases, the risk increases with age. The genetic test cannot predict the exact moment in which the disease will develop but gives enough information about the risk.

NGOncology will help you determine if there is increased probability of developing some of the most common malignant and benign diseases, thus, will enable you to know yours and your children’s risk and how to minimize it.

Some of the mutations we investigate have proven to be crucial for the development of specific types of cancer. Others are related to vital processes important for different types of cells, and mutations in those genes can lead to cancer in various body tissues.

NGOncology will help you:

• Identify the risk of developing certain types of cancers (breast, ovary, prostate, skin, colon, etc.) as well as some benign tumors
• Determine the possibility of transmitting the risk for the development of malignancy in subsequent generations
• Determine the risk for other relatives
• Provide thorough information, determine the consequences and the possibilities for action
• Provide consultations with specialist (oncologist, gynecologist, endocrinologist, etc.) if necessary

The genetic test cannot definitely determine whether you will develop cancer, but can identify how high the risk of oncological diseases is.

• If you have malignancies or benign tumors in your family
• If you have relative with cancer that occurred at an early age
• If your relative has established hereditary cancer
• If you have had cancer in the past
• If you want to know your risk for developing hereditary oncological diseases
• If you want to know the possibility of transmitting the risk for the development of malignancy in subsequent generations

NGOncology targets 94 genes, previously linked to predisposition towards various types of cancer. The TruSight Cancer sequencing panel includes genes associated with both common (e.g., breast, colorectal) and rare hereditary cancers. Content selection is based on expert curation of the scientific literature and other high-quality resources.

Databases used for results interpretation:

1. HumanGeneMutationDatabase (HGMD) (http://www.hgmd.cf.ac.uk/ac/index.php)
2. ShortGeneticVariationsdatabase(dbSNP) (http://www.ncbi.nlm.nih.gov/projects/SNP/)
3. OMIM (http://www.ncbi.nlm.nih.gov/omim)
4. NHLBI ExomeSequencing Project (ESP) ExomeVariant Server (http://evs.gs.washington.edu/EVS/)
5. ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/)

International Standards and Guidelines for the interpretation and reporting of sequence variants:

• Pathogenic variants – mutations that lead to disease and are associated with particular disease phenotype
• Likely pathogenic variants – data in favor of pathogenic effect of the variations
• Variants of Unknown Significance – controversial pathogenicity data or insufficient data at the time of the study
• Likely benign variants – evidence against the pathogenic nature of the variants
• Variants with clinical association – behavior of variants based on the individual or family history of the disease

Please call us on +359 888 842 200 to find out more about our leasing options.